Ozempic vs Wegovy vs Mounjaro: A Clinical Guide to GLP-1 Medications

The arrival of GLP-1 receptor agonists — semaglutide and tirzepatide — has fundamentally changed the landscape of obesity and Type 2 diabetes medicine. Patients are arriving at consultations with questions about Ozempic, Wegovy, Mounjaro, and Zepbound: are they the same drug? Which one works better? What are the risks? This guide provides a clinical, evidence-based comparison to help you make an informed decision with your physician.

What Are GLP-1 Receptor Agonists?

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by L-cells in the small intestine in response to food intake. It exerts multiple metabolic effects: stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and signalling satiety through hypothalamic GLP-1 receptors.^[1] The result is lower post-meal glucose, reduced appetite, and decreased caloric intake.

Native GLP-1 has a plasma half-life of only 1–2 minutes due to rapid degradation by the enzyme DPP-4. Pharmaceutical GLP-1 receptor agonists are modified peptides with extended half-lives, allowing once-weekly dosing.

Semaglutide: Ozempic and Wegovy — Same Molecule, Different Doses

Semaglutide is a 94% homologous analogue of human GLP-1, modified with a C18 fatty acid chain linked via a mini-PEG linker to extend its half-life to approximately 7 days, enabling once-weekly injection.^[2]

Ozempic (semaglutide 0.5mg, 1mg, 2mg weekly) is licensed for Type 2 diabetes management. It reduces HbA1c by 1.1–1.8% and produces average weight loss of 5–6 kg at the 1mg dose in the SUSTAIN trial series.^[3]

Wegovy (semaglutide 2.4mg weekly) is licensed for chronic weight management in adults with BMI ≥30 kg/m² (or ≥27 with weight-related comorbidities). The STEP 1 trial demonstrated average weight loss of 14.9% of body weight at 68 weeks versus 2.4% with placebo.^[4] Crucially, 50% of Wegovy-treated participants lost more than 15% of body weight, and 32% lost more than 20%.

The STEP 2 trial, conducted specifically in patients with Type 2 diabetes, showed 9.6% average weight loss and HbA1c reduction of 1.6 percentage points at 68 weeks.^[5] Diabetes patients lose less weight on average than non-diabetic patients — a consistent finding across the GLP-1 class, related to the protective effect of higher baseline insulin levels.

Oral Semaglutide: Rybelsus

Rybelsus (semaglutide 7mg and 14mg oral tablets) delivers semaglutide with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]). It must be taken on an empty stomach with no more than 120mL of water, 30 minutes before any food. Bioavailability is approximately 1% — compared to subcutaneous injection — but clinical trials (PIONEER series) demonstrate HbA1c reductions of 1.2–1.4% and weight loss of 4–5 kg, making it effective for patients who prefer oral administration.^[6]

Tirzepatide: Mounjaro and Zepbound — The Dual Agonist

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is a novel dual GIP/GLP-1 receptor agonist — the first of a new class called twincretins. It is a 39-amino acid peptide that co-activates both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor, with balanced activity at both.^[7]

The SURPASS clinical trial programme compared tirzepatide directly against semaglutide. SURPASS-2 demonstrated that tirzepatide 15mg weekly produced HbA1c reductions of 2.3% and weight loss of 11.2 kg — significantly greater than semaglutide 1mg (1.86% HbA1c reduction, 5.7 kg weight loss).^[8]

For obesity, the SURMOUNT-1 trial (Zepbound) demonstrated average weight loss of 22.5% of body weight at the 15mg dose over 72 weeks — the largest weight loss ever demonstrated in a pharmacological trial.^[9] 63% of participants lost 20% or more of body weight.

Head-to-Head: Semaglutide vs Tirzepatide (SURMOUNT-5)

The SURMOUNT-5 trial, published in 2025, was the first direct head-to-head comparison of Zepbound (tirzepatide) versus Wegovy (semaglutide) for obesity. At 72 weeks, tirzepatide produced 20.2% mean weight loss compared to 13.7% with semaglutide — a statistically significant difference of 6.5 percentage points in favour of tirzepatide.^[10] These are the most impactful pharmacological obesity results ever recorded in a randomised head-to-head trial.

Safety and Side Effects: What to Expect

The most common adverse effects of both semaglutide and tirzepatide are gastrointestinal: nausea (30–44%), vomiting (10–24%), diarrhoea (20–30%), and constipation (10–24%).^[3,4,7,9] These are dose-dependent and most pronounced during the initial dose-escalation period. Starting at low doses and increasing gradually every 4 weeks mitigates most GI side effects.

Rare but serious adverse events include:^[2,7]

• Pancreatitis: Rare (<0.3%). Should be monitored in patients with a history of pancreatitis.
• Gallbladder disease: Cholelithiasis and cholecystitis risk is increased, likely due to rapid weight loss and changes in bile composition.
• Thyroid C-cell tumours: A class warning based on rodent studies; not observed in human clinical trials. Contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2.
• Diabetic retinopathy worsening: A rapid fall in HbA1c (particularly from very high levels) has been associated with transient worsening of pre-existing retinopathy.

Cardiovascular Benefits: Beyond Weight and Glucose

The SELECT trial (2023) demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events (MACE — cardiovascular death, non-fatal MI, non-fatal stroke) by 20% in adults with established cardiovascular disease and obesity, but without diabetes, over a mean follow-up of 33.7 months.^[11] This landmark finding led to expanded approval and represents a major advance in cardiovascular medicine.

Tirzepatide’s SURPASS-CVOT trial is ongoing, with results anticipated in 2026.

Which Medication Should You Choose?

The decision between semaglutide and tirzepatide depends on multiple factors that must be evaluated in a physician consultation:

• Primary goal: For Type 2 diabetes primarily, Ozempic (semaglutide) has the longest cardiovascular safety track record. For maximum weight loss, tirzepatide (Mounjaro/Zepbound) demonstrates superior efficacy.
• Cost and insurance: In many markets, tirzepatide is more expensive. Generic semaglutide (compounded) availability varies by jurisdiction and regulatory status.
• GI tolerance: Tirzepatide may have a more favourable GI tolerability profile due to its GIP component; some patients who could not tolerate semaglutide tolerate tirzepatide well.
• Cardiovascular history: In patients with established ASCVD, semaglutide has the most robust, published cardiovascular outcome data.